Italia markets closed
Dow Jones
39.872,99 +66,22 (+0,17%) Nasdaq
16.832,62 +37,75 (+0,22%) Nikkei 225
38.946,93 -122,75 (-0,31%) EUR/USD
1,0858 -0,0004 (-0,03%) Bitcoin EUR
64.170,38 +27,77 (+0,04%) CMC Crypto 200
1.510,62 +22,08 (+1,48%)
NVCR Sep 2024 22.500 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:45AM EDT. Mercato aperto.
| Chiusura precedente | 4,8200 |
| Aperto | 4,5000 |
| Denaro | 3,6000 |
| Lettera | 4,1000 |
| Prezzo d'esercizio | 22,50 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 4,5000 - 4,5000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 222 |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.